SLABÝ, Ondřej. Non-coding RNAs as Biomarkers for Colorectal Cancer Screening and Early Detection. In Slaby O; Calin GA. Non-coding RNAs in Colorectal Cancer. CHAM: SPRINGER INT PUBLISHING AG, 2016, p. 153-170. Advances in Experimental Medicine and Biology 937. ISBN 978-3-319-42057-8. Available from: https://dx.doi.org/10.1007/978-3-319-42059-2_8.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Non-coding RNAs as Biomarkers for Colorectal Cancer Screening and Early Detection
Authors SLABÝ, Ondřej (203 Czech Republic, guarantor, belonging to the institution).
Edition CHAM, Non-coding RNAs in Colorectal Cancer, p. 153-170, 18 pp. Advances in Experimental Medicine and Biology 937, 2016.
Publisher SPRINGER INT PUBLISHING AG
Other information
Original language English
Type of outcome Chapter(s) of a specialized book
Field of Study 30200 3.2 Clinical medicine
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
WWW URL
RIV identification code RIV/00216224:14740/16:00098133
Organization unit Central European Institute of Technology
ISBN 978-3-319-42057-8
Doi http://dx.doi.org/10.1007/978-3-319-42059-2_8
UT WoS 000399043400009
Keywords in English Colorectal cancer; Non-coding RNA; microRNA; lncRNA; piRNAs; snoRNAs; snRNAs; Screening; Early diagnosis
Tags rivok
Changed by Changed by: Mgr. Eva Špillingová, učo 110713. Changed: 7/11/2017 15:18.
Abstract
Early detection of colorectal cancer (CRC) is the key for prevention and the ability to impact long-term survival of CRC patients. Current CRC screening modalities are inadequate for global application because of low sensitivity and specifi city in case of conventional stool-based screening tests, and high costs and a low participation compliance in colonoscopy. An accurate stool-or blood-based screening test with use of innovative biomarkers is an appealing alternative as it is non-invasive and poses minimal risk to patients. It is easy to perform, can be repeated at shorter intervals, and therefore would likely lead to a much higher compliance rates. Non-coding RNAs (ncRNAs) have recently gained attention because of their involvement in different biological processes, such as proliferation, differentiation, migration, angiogenesis and apoptosis. An increasing number of studies have demonstrated that mutations or abnormal expression of ncRNAs are closely associated with various cancers, including CRC. The discovery that ncRNAs (mainly microRNAs) are stable in stool and in blood plasma and serum presents the opportunity to develop novel strategies taking advantage of circulating ncRNAs as early diagnostic biomarkers of CRC. This chapter is a comprehensive examination of aberrant ncRNAs expression levels in tumor tissue, stool and blood of CRC patients and a summary of the current fi ndings on ncRNAs, including microRNAs, small nucleolar RNAs, small nuclear RNAs, Piwi-interacting RNAs, circular RNAs and long ncRNAs in regards to their potential usage for screening or early detection of CRC.
PrintDisplayed: 9/9/2024 02:23